SCHEMBL5361265

SCHEMBL5361265

Cc1cc(Cl)ccc1NC(=S)NN=Cc1cc([N+](=O)[O-])cc([N+](=O)[O-])c1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 14/20 0.61
KDM4E B2RXH2 7/20 0.61
TDP1 Q9NUW8 4/20 0.61
SAE1 Q9UBE0 2/20 0.61
UBA2 Q9UBT2 2/20 0.61
CASP3 P42574 2/20 0.61
SENP8 Q96LD8 2/20 0.61
SENP7 Q9BQF6 2/20 0.61
SENP6 Q9GZR1 2/20 0.61
KMT2A Q03164 6/20 0.57
MEN1 O00255 5/20 0.57
ALDH1A1 P00352 7/20 0.52
LMNA P02545 5/20 0.52
MCL1 Q07820 3/20 0.52
MAPK1 P28482 2/20 0.52
NPSR1 Q6W5P4 2/20 0.52
GAA P10253 1/20 0.52
THRB P10828 1/20 0.52
RECQL P46063 1/20 0.52
BLM P54132 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5361260 1.00 MAPT (0.61) MAPTKDM4ETDP1SAE1UBA2
SCHEMBL5363022 0.87 MAPT (0.56) MAPTKDM4ETDP1SAE1UBA2
SCHEMBL5363026 0.87 MAPT (0.56) MAPTKDM4ETDP1SAE1UBA2
SCHEMBL5179611 0.74 LMNA (0.60) MAPTKDM4ETDP1CASP3SENP8
SCHEMBL5179613 0.74 LMNA (0.60) MAPTKDM4ETDP1CASP3SENP8
SCHEMBL12530464 0.71 ALDH1A1 (0.57) MAPTKDM4ETDP1KMT2AMEN1
SCHEMBL5181626 0.69 MEN1 (0.74) MAPTKMT2AMEN1ALDH1A1LMNA
SCHEMBL5181623 0.69 MEN1 (0.74) MAPTKMT2AMEN1ALDH1A1LMNA
SCHEMBL5181384 0.67 MAPT (0.76) MAPTKDM4EKMT2AMEN1ALDH1A1
SCHEMBL5181391 0.67 MAPT (0.76) MAPTKDM4EKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US claimed
US-7241783-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2007-07-10 US disclosed
EP-1349613-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2005-09-21 EP disclosed
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US disclosed
EP-1349613-A2 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2003-10-08 EP disclosed
WO-2002049413-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058990-A1 Thrombopoietin mimetics MPL, THPO, TEK MAPT 4635/4885KDM4E 3460/4885TDP1 4062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.